Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia

Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination

(2023) Hyunbin D. Huh et al.   Molecular Cancer

Acute myeloid leukemia: current progress and future directions

(2021) Hagop Kantarjian et al.   Blood Cancer Journal

Towards precision medicine for AML

(2021) Hartmut Döhner et al.   Nature Reviews Clinical Oncology

Hot Spot Analysis of YAP-TEAD Protein-Protein Interaction Using the Fragment Molecular Orbital Method and Its Application for Inhibitor Discovery

(2021) Jongwan Kim et al.   Cancers

Response and Resistance to BCR-ABL1-Targeted Therapies

(2020) Theodore P. Braun et al.   CANCER CELL

Targeting FLT3 mutations in AML: review of current knowledge and evidence

(2019) Naval Daver et al.   LEUKEMIA

Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival

(2019) Brett M. Noel et al.   JOURNAL OF PROTEOME RESEARCH

FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications

(2019) Julhash U. Kazi et al.   PHYSIOLOGICAL REVIEWS

Regulation of TEAD Transcription Factors in Cancer Biology

(2019) Hyunbin D. Huh et al.   Cells

YAP and TAZ are dispensable for physiological and malignant haematopoiesis

(2018) Elisa Donato et al.   LEUKEMIA

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

(2018) Simona Soverini et al.   Molecular Cancer

CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting

(2017) Niklas Landberg et al.   HAEMATOLOGICA

RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia

(2017) Ayuna Hattori et al.   LEUKEMIA RESEARCH

CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting

(2017) Niklas Landberg et al.   HAEMATOLOGICA

Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche

(2016) Haobin Ye et al.   Cell Stem Cell

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway

(2015) Jung-Soon Mo et al.   NATURE CELL BIOLOGY

Allogeneic transplantation for CML in the TKI era: striking the right balance

(2015) Andrew J. Innes et al.   Nature Reviews Clinical Oncology

Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers

(2014) Francesca Cottini et al.   NATURE MEDICINE

Biomarkers for determining the prognosis in chronic myelogenous leukemia

(2013) Kendra Sweet et al.   Journal of Hematology & Oncology

How I treat CML blast crisis

(2012) R. Hehlmann   BLOOD

Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis

(2012) B. Zhao et al.   GENES & DEVELOPMENT

Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

(2011) J. M. Gozgit et al.   MOLECULAR CANCER THERAPEUTICS